Disease Overview
As the most common risk factor for cardiovascular diseases, hypertension is the costliest primary and secondary healthcare condition worldwide. Hypertension refers to persistent, abnormally elevated blood pressure. Several risk factors are known to contribute to hypertension, despite the main etiology remaining unknown.
Market Snapshot
As the most common risk factor for cardiovascular diseases, hypertension is the costliest primary and secondary healthcare condition worldwide. Hypertension refers to persistent, abnormally elevated blood pressure. Several risk factors are known to contribute to hypertension, despite the main etiology remaining unknown.
Market Snapshot
- The hypertension market is highly genericized, and fixed-dose combinations are likely to drive the sales of branded drugs.
- Multi-class combinations are common in the treatment of hypertension but preferences differ by market.
- Prevalent cases are expected to increase by 17% over the forecast period, contributing to an enormous disease burden.
- Sales of the Benicar franchise have declined since the drug’s patent expiry in October 2016.
- Drug development rates in hypertension have declined in recent years due to the competitive nature of this disease market.
Table of Contents
EPIDEMIOLOGY: SYSTEMIC HYPERTENSION (Published on 18 June 2018)Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources
LIST OF FIGURES
Figure 1: Trends in total prevalent cases of systemic hypertension in the US, Japan, and five major EU markets, by country, 2017–37
LIST OF TABLES
Table 1: Systemic hypertension classification according to ACC/AHA guidelines
Table 2: Sources used for the epidemiological analysis of systemic hypertension in the US, Japan, and five major EU markets, by country
Table 3: Prevalent cases of systemic hypertension in the US, Japan, and five major EU markets, by country, 2017–37
